How to Buy a Pharmacy in 2026

Pharmacy acquisitions are unlike anything else in healthcare M&A. I've advised on transactions across dozens of healthcare verticals, and pharmacy consistently has the most regulatory complexity per dollar of deal value. You're not just buying a business — you're buying a DEA registration, a state Board of Pharmacy license, a web of PBM contracts, PSAO membership, and potentially 340B eligibility that took years to establish. Miss any one of these in your due diligence, and you can find yourself owning a store that can't legally fill prescriptions.

That said, there are real opportunities in pharmacy right now. The independent pharmacy landscape is consolidating, many pharmacist-owners are approaching retirement age, and buyers who understand the regulatory terrain can acquire profitable pharmacies at reasonable multiples. Let me walk you through what you need to know.

The Regulatory Transfer Gauntlet

Before you analyze a single financial statement, you need to understand the licensing and regulatory framework. This is where most pharmacy deals get complicated — and where experienced buyers gain an edge over first-timers.

State Board of Pharmacy license. Every pharmacy operates under a state-issued license. When ownership changes, you need to apply for a new pharmacy permit or transfer the existing one. Timelines vary dramatically by state — Texas can take 8-12 weeks, California often takes 4-6 months, and New York can take 6-9 months. You cannot operate the pharmacy under new ownership until this transfer is approved. This means you either need to structure the deal as an asset purchase with a transition services agreement (seller continues operating until your license clears) or buy the entity (stock/membership interest purchase) which may not trigger a new license requirement in some states. Your healthcare attorney needs to advise on the best structure for your state.

DEA registration. The pharmacy's DEA registration allows it to handle controlled substances. Like the pharmacy license, a change of ownership typically requires a new DEA registration. The good news: DEA applications process faster than state boards, usually 4-8 weeks. The bad news: any gap in DEA registration means you cannot dispense Schedule II-V medications, which can be 20-30% of your prescription volume.

PBM network participation. This is the one that catches buyers off guard. Your pharmacy fills prescriptions because it's in-network with pharmacy benefit managers like Express Scripts, CVS Caremark, and OptumRx. These PBM contracts don't automatically transfer with a change of ownership. You need to apply for credentialing with each PBM, and until approved, you cannot adjudicate claims through their network. A gap in PBM participation can devastate your revenue overnight. Start PBM applications the day you sign the LOI.

PSAO membership. Most independent pharmacies belong to a Pharmacy Services Administrative Organization (PSAO) — groups like McKesson's Health Mart, AmerisourceBergen's Good Neighbor Pharmacy, or Cardinal Health's Medicine Shoppe. The PSAO negotiates PBM reimbursement rates on behalf of its members. Transferring PSAO membership or joining a new one needs to happen in coordination with your PBM credentialing. The PSAO you choose directly impacts your reimbursement rates and, therefore, your gross margins.

340B: The Hidden Goldmine (or Trap)

If the pharmacy you're acquiring participates in the 340B Drug Pricing Program, this single factor can be worth more than the rest of the business combined. The 340B program allows eligible entities (federally qualified health centers, disproportionate share hospitals, certain clinics) to purchase outpatient drugs at deeply discounted prices — often 25-50% below wholesale acquisition cost — and then bill insurers at standard reimbursement rates. The spread is enormous.

A pharmacy contracting with 340B-eligible entities can generate $500K-$2M in incremental annual gross profit from the program alone. When I see a pharmacy with strong 340B relationships, the valuation math changes completely. Instead of a standard 2-3x SDE multiple, you might see 4-6x because of the 340B cash flow stream.

The trap: 340B eligibility belongs to the covered entity (the FQHC or hospital), not the pharmacy. If you're buying a contract pharmacy that fills 340B prescriptions, you need to verify that the covered entity will continue the relationship post-acquisition. I've seen deals where the 340B contract terminated at change of ownership, wiping out 40% of the pharmacy's gross profit overnight. Get written confirmation from every 340B covered entity that they intend to continue the contract pharmacy arrangement.

What a Pharmacy Is Actually Worth

Pharmacy valuations in 2026 run on two primary metrics: prescription volume and SDE. Here's what I'm seeing in closed transactions:

• Standard retail pharmacy: 1.5-3x SDE, or $3-5 per prescription (annual volume). A pharmacy filling 200 scripts/day with $400K SDE might sell for $800K-$1.2M.
• Pharmacy with 340B contracts: 3-6x SDE. The 340B cash flow stream is recurring and high-margin, which justifies the premium.
• Specialty/compounding pharmacy: 3-5x SDE for established operations with referral networks. Specialty pharmacies dispensing high-cost biologics or oncology drugs can have $10-30M in revenue with thin-but-predictable margins.
• Long-term care pharmacy: 4-7x EBITDA. Facility contracts create predictable, recurring revenue. A pharmacy servicing 20+ nursing homes or assisted living facilities is a stable, defensible business.

One critical nuance: inventory is typically 20-30% of the total deal value in pharmacy acquisitions, and it's usually purchased separately at cost. A $1M pharmacy acquisition might have $250K in inventory on top of the business purchase price. Make sure your financing covers both.

Due Diligence: What to Verify Beyond the Financials

Reimbursement trends. Pull the pharmacy's dispensing data for the past three years and calculate effective reimbursement rate per prescription. PBMs have systematically reduced reimbursement rates by 3-5% annually for the past decade. If the pharmacy's per-script margin is declining, you need to model that trend forward and determine whether current profitability is sustainable.

DIR fee exposure. Direct and indirect remuneration fees are retroactive clawbacks from PBMs that can eat 3-8% of a pharmacy's gross revenue. These fees are assessed months after dispensing, making them difficult to forecast. Ask for the pharmacy's DIR fee history for the past 24 months and factor the run-rate into your cash flow projections. DIR fees have been the number one margin killer for independent pharmacies since 2020.

Pharmacist and technician staffing. You need licensed pharmacists to operate. If the owner is the only pharmacist, you have a critical dependency. Pharmacist salaries have risen to $130-160K in most markets, and recruiting takes 3-6 months. Verify that the pharmacy has adequate staffing to operate without the selling pharmacist-owner, or negotiate a transition period of 6-12 months.

Prescription transfer risk. Unlike most businesses, pharmacy customers can transfer their prescriptions to a competitor with a single phone call. Customer retention in pharmacy averages 85-90% post-acquisition, but that 10-15% attrition can be devastating if it includes your highest-margin patients. Patients who fill specialty medications or have been with the pharmacy for 10+ years are the stickiest.

Specialty vs. Retail: Two Different Businesses

The independent retail pharmacy filling 150-250 scripts per day of generic maintenance medications is a fundamentally different business than a compounding pharmacy or a specialty pharmacy dispensing $50,000-per-month oncology drugs.

Retail pharmacies compete on convenience and service against CVS and Walgreens. Their margins are thin (gross margins of 22-28%) and getting thinner as PBMs squeeze reimbursement. The path to profitability in retail is volume, ancillary services (immunizations, MTM, point-of-care testing), and front-end retail sales.

Specialty and compounding pharmacies compete on clinical expertise and physician relationships. Their margins are often higher (30-45% gross for compounding), the revenue per prescription is dramatically higher, and the competitive moat is deeper because it's built on clinical capabilities rather than location convenience. However, they carry higher regulatory risk — compounding pharmacies operate under FDA and state board scrutiny that can change the business model overnight, as the 2012 NECC meningitis outbreak and subsequent DQSA legislation demonstrated.

Financing a Pharmacy Acquisition

SBA 7(a) loans are widely available for pharmacy acquisitions under $5M. Lenders view pharmacies favorably because of predictable cash flows and essential service designation. The inventory component is typically financed through the primary wholesaler (McKesson, AmerisourceBergen, Cardinal Health) on net-30 to net-60 terms rather than through the acquisition loan.

For larger deals, conventional healthcare lending through banks like Live Oak, Bank of America Practice Solutions, or specialized pharmacy lenders is standard. Expect 15-25% equity contribution, 7-10 year terms, and covenants around prescription volume maintenance and reimbursement rate floors.

The Bottom Line

Buying a pharmacy is a regulatory obstacle course wrapped around a profitable business. The pharmacies that are worth buying in 2026 have strong prescription volume, diversified payer mix, 340B relationships or specialty capabilities, and a staff pharmacist who isn't the owner. The ones to avoid are standard retail operations with declining scripts, heavy PBM concentration, and no differentiation from the CVS down the street. Do your regulatory homework before you fall in love with the financials — because in pharmacy, a licensing gap or PBM contract lapse can turn a good deal into a nightmare faster than any other industry I've worked in.